NCT04975555View on ClinicalTrials.gov

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Cytokine Release SyndromeICANSLymphoma, Non-HodgkinMultiple MyelomaAcute Lymphoblastic Leukemia

Interventions

DRUG

Siltuximab

Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors

lead

University of Alabama at Birmingham

OTHER